Fate Therapeutics Inc (NASDAQ:FATE)

4.87
Delayed Data
As of Jun 09
 -0.435 / -8.21%
Today’s Change
4.02
Today|||52-Week Range
37.13
-51.78%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$516.5M

Company Description

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Contact Information

Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego California 92131
P:(858) 875-1800
Investor Relations:

Employees

Shareholders

Other institutional58.84%
Mutual fund holders51.90%
Individual stakeholders21.53%

Top Executives

J. Scott WolchkoPresident, Chief Executive Officer & Director
Edward J. DulacChief Financial Officer & Accounting Officer
Bahram ValamehrChief Research & Development Officer
Wen Bo WangSenior Vice President-Technical Operations
Yu Waye ChuChief Medical Officer